Enhancing laboratory capacity during Ebola virus disease (EVD) heightened surveillance in Liberia: lessons learned and recommendations.


Journal

The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926

Informations de publication

Date de publication:
2019
Historique:
received: 24 10 2018
accepted: 28 01 2019
entrez: 13 8 2019
pubmed: 14 8 2019
medline: 7 9 2019
Statut: epublish

Résumé

Following a declaration by the World Health Organization that Liberia had successfully interrupted Ebola virus transmission on May 9th, 2015; the country entered a period of enhanced surveillance. The number of cases had significantly reduced prior to the declaration, leading to closure of eight out of eleven Ebola testing laboratories. Enhanced surveillance led to an abrupt increase in demand for laboratory services. We report interventions, achievements, lessons learned and recommendations drawn from enhancing laboratory capacity. Using archived data, we reported before and after interventions that aimed at increasing laboratory capacity. Laboratory capacity was defined by number of laboratories with Ebola Virus Disease (EVD) testing capacity, number of competent staff, number of specimens tested, specimen backlog, daily and surge testing capacity, and turnaround time. Using Stata 14 (Stata Corporation, College Station, TX, USA), medians and trends were reported for all continuous variables. Between May and December 2015, interventions including recruitment and training of eight staff, establishment of one EVD laboratory facility, implementation of ten Ebola GeneXpert diagnostic platforms, and establishment of working shifts yielded an 8-fold increase in number of specimens tested, a reduction in specimens backlog to zero, and restoration of turn-around time to 24 hours. This enabled a more efficient surveillance system that facilitated timely detection and containment of two EVD clusters observed thereafter. Effective enhancement of laboratory services during high demand periods requires a combination of context-specific interventions. Building and ensuring sustainability of local capacity is an integral part of effective surveillance and disease outbreak response efforts.

Identifiants

pubmed: 31404295
doi: 10.11604/pamj.supp.2019.33.2.17366
pii: PAMJ-SUPP-33-2-08
pmc: PMC6675925
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

J Med Virol. 2000 Apr;60(4):463-7
pubmed: 10686031
J Virol. 2004 Apr;78(8):4330-41
pubmed: 15047846
Bull Soc Pathol Exot. 2005 Sep;98(3):205-9
pubmed: 16267962
MMWR Morb Mortal Wkly Rep. 2014 Jun 27;63(25):548-51
pubmed: 24964881
MMWR Morb Mortal Wkly Rep. 2014 Nov 21;63(46):1072-6
pubmed: 25412066
MMWR Morb Mortal Wkly Rep. 2014 Nov 21;63(46):1082-6
pubmed: 25412068
Afr J Med Med Sci. 2014 Jun;43(2):87-97
pubmed: 25474983
MMWR Morb Mortal Wkly Rep. 2014 Dec 19;63(50):1202-4
pubmed: 25522089
Euro Surveill. 2015 Mar 26;20(12):null
pubmed: 25846492
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):479-81
pubmed: 25950255
MMWR Morb Mortal Wkly Rep. 2015 May 15;64(18):500-4
pubmed: 25974635
PLoS Curr. 2015 May 06;7:null
pubmed: 26064783
J Infect Dis. 2017 Jun 15;215(12):1799-1806
pubmed: 28520958

Auteurs

Victoria Katawera (V)

World Health Organization, Monrovia, Liberia.

Henry Kohar (H)

Ministry of Health, Monrovia, Liberia.

Nuha Mahmoud (N)

World Health Organization, Monrovia, Liberia.

Philomena Raftery (P)

World Health Organization, Monrovia, Liberia.

Christine Wasunna (C)

Formarly Academic Consortium Combating Ebola in Liberia, Monrovia, Liberia.

Ben Humrighouse (B)

United States Centers for Disease Control and Prevention, Atlanta, United States of America.

Patrick Hardy (P)

Ministry of Health, Monrovia, Liberia.

John Saindon (J)

United States Centers for Disease Control and Prevention, Atlanta, United States of America.

Randal Schoepp (R)

United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America.

Monear Makvandi (M)

Sandia National Laboratories, Albuquerque, New Mexico, United States of America.

Lisa Hensley (L)

National Institutes of Health,Bethesda, United States of America.

Orla Condell (O)

World Health Organization, Monrovia, Liberia.

Kara Durski (K)

World Health Organization, Geneva, Switzerland.

Shalini Singaravelu (S)

World Health Organization, Geneva, Switzerland.

Laetitia Gahimbare (L)

World Health Organization, Monrovia, Liberia.

Gene Olinger (G)

National Institutes of Health,Bethesda, United States of America.

Francis Kateh (F)

Ministry of Health, Monrovia, Liberia.

Dhamari Naidoo (D)

World Health Organization, Geneva, Switzerland.

Peter Nsubuga (P)

Global Public Health Solutions, Atlanta, Georgia, United States of America.

Pierre Formenty (P)

World Health Organization, Geneva, Switzerland.

Tolbert Nyenswah (T)

Ministry of Health, Monrovia, Liberia.

Sheick Oumar Coulibaly (SO)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Joseph Chukwudi Okeibunor (JC)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ambrose Talisuna (A)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ali Ahmed Yahaya (AA)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Soatiana Rajatonirina (S)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Desmond Williams (D)

United States Centers for Disease Control and Prevention, Atlanta, United States of America.

Bernice Dahn (B)

Ministry of Health, Monrovia, Liberia.

Alex Gasasira (A)

World Health Organization, Monrovia, Liberia.
Ministry of Health, Monrovia, Liberia.
Formarly Academic Consortium Combating Ebola in Liberia, Monrovia, Liberia.
United States Centers for Disease Control and Prevention, Atlanta, United States of America.
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America.
Sandia National Laboratories, Albuquerque, New Mexico, United States of America.
National Institutes of Health,Bethesda, United States of America.
World Health Organization, Geneva, Switzerland.
Global Public Health Solutions, Atlanta, Georgia, United States of America.
World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Ibrahima Socé Fall (IS)

World Health Organization, Regional Office for Africa, Brazzaville, Congo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH